Epidermal growth factor receptor and variant III targeted immunotherapy

Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been tar...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2014-10, Vol.16 Suppl 8 (suppl 8), p.viii20-viii25
Main Authors: Congdon, Kendra L, Gedeon, Patrick C, Suryadevara, Carter M, Caruso, Hillary G, Cooper, Laurence J N, Heimberger, Amy B, Sampson, John H
Format: Article
Language:English
Subjects:
Animals
Brain Neoplasms
Cell- and Tissue-Based Therapy
Glioma - immunology
Glioma - therapy
Humans
Immunotherapy
Invited Reviews
Receptor, Epidermal Growth Factor - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route of delivery, target selection and the immune-mediated approach undertaken must work together to maximize efficacy with safety. Selected tumor-specific targets can spare potential toxicity to normal tissue; however, they are far less common than tumor-associated antigens and may not be present on all patients. In the context of immunotherapy for high-grade glioma, 2 of the most prominently studied antigens are the tumor-associated epidermal growth factor receptor and its tumor-specific genetic deletion variant III. In this review, we will summarize the immune-mediated strategies employed against these targets as well as the caveats particular to these approaches.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/nou236